The long standing Hematology T32 Training Grant at the University of North Carolina at Chapel Hill (UNC-CH) remains committed to training both MD physician-scientists and PhD scientists for careers in academic hematology and hematology research. This program will continue to train adult and pediatric hematology fellows and PhD post- doctoral candidates in areas of traditional institutional research strengths encompassing benign hematology. Both basic bench and clinical research tracks are available, with carefully selected didactic coursework to complement the training experience. In this competitive renewal application, scientific and educational interactions between MD and PhD trainees in the form of conferences, journal clubs, and symposia have been emphasized. Following 2 years of training on the T32 grant, trainees will be encouraged to apply for individual or institutional K series awards, and/or other sources of independent funding.
For over 35 years, the training program in academic hematology at the University of North Carolina at Chapel Hill (UNC-CH) has benefitted from support by the Ruth L. Kirschstein National Research Service Award. This program, which encompasses disorders of the blood, vasculature or immune system, has been extraordinarily successful in its mission to train clinical and bench researchers in hematology. The cornerstones of training include a mentored research project, focused seminars and conferences, training in the responsible conduct of research, and didactic coursework in clinical research, laboratory methodology, grantsmanship, and the academic community. Both MD and PhD postdoctoral candidates are recruited from intramural and extramural sources, and their frequent interaction during the 2-year period of support engenders a mutual respect and understanding of the ultimate goals of biomedical research in hematologic disorders.
|Hisada, Yohei; Thålin, Charlotte; Lundström, Staffan et al. (2018) Comparison of microvesicle tissue factor activity in non-cancer severely ill patients and cancer patients. Thromb Res 165:1-5|
|Beckman, Joan D; Kasthuri, Raj S; Wolberg, Alisa S et al. (2018) Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors. Haemophilia 24:e417-e420|
|Klein, Mia; Chang, Alicia K; Vasudevan, Sanjeev A et al. (2018) Clinically significant ascites as an indication for resection of rapidly involuting congenital hepatic hemangiomas. Pediatr Blood Cancer 65:e27222|
|Beckman, Joan D; Rollins-Raval, Marian A; Raval, Jay S et al. (2018) Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura. Am J Ther 25:e270-e272|
|Beckman, J D; Holle, L A; Wolberg, A S (2018) Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin ?-chain crosslinking. J Thromb Haemost 16:131-141|
|Hisada, Yohei; Mackman, Nigel (2018) Mouse models of cancer-associated thrombosis. Thromb Res 164 Suppl 1:S48-S53|
|Pahl, Kristy S; Kim, Kyung; Sams, Casey et al. (2018) Inconsistency in classifying vascular anomalies: What's in a name? Pediatr Blood Cancer 65:|
|Houghton, Damon E; Moll, Stephan (2017) Antiphospholipid antibodies. Vasc Med 22:545-550|
|Martin, Karlyn A; Lee, Craig R; Farrell, Timothy M et al. (2017) Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. Am J Med 130:517-524|
|Houghton, Damon E; Sud, Shivani; Moll, Stephan et al. (2017) Perils in the thrombophilia workup: Frequency and circumstances of erroneously ordered factor V activity tests for thrombophilia. Vasc Med 22:527-528|
Showing the most recent 10 out of 72 publications